vs
Beam Therapeutics Inc.（BEAM）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的3.2倍（$114.1M vs $35.5M），Beam Therapeutics Inc.净利率更高（214.1% vs -304.2%，领先518.3%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 279.5%），RECURSION PHARMACEUTICALS, INC.自由现金流更多（$-47.3M vs $-87.0M）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
BEAM vs RXRX — 直观对比
营收规模更大
BEAM
是对方的3.2倍
$35.5M
营收增速更快
RXRX
高出402.2%
279.5%
净利率更高
BEAM
高出518.3%
-304.2%
自由现金流更多
RXRX
多$39.7M
$-87.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $35.5M |
| 净利润 | $244.3M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -15.3% | -304.8% |
| 净利率 | 214.1% | -304.2% |
| 营收同比 | 279.5% | 681.7% |
| 净利润同比 | 370.4% | 39.6% |
| 每股收益（稀释后） | $2.53 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMRXRX
| Q4 25 | $114.1M | $35.5M | ||
| Q3 25 | — | $5.2M | ||
| Q2 25 | — | $19.2M | ||
| Q1 25 | — | $14.7M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $26.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $13.8M |
净利润BEAMRXRX
| Q4 25 | $244.3M | $-108.1M | ||
| Q3 25 | — | $-162.3M | ||
| Q2 25 | — | $-171.9M | ||
| Q1 25 | — | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | — | $-95.8M | ||
| Q2 24 | — | $-97.5M | ||
| Q1 24 | — | $-91.4M |
毛利率BEAMRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率BEAMRXRX
| Q4 25 | -15.3% | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率BEAMRXRX
| Q4 25 | 214.1% | -304.2% | ||
| Q3 25 | — | -3135.3% | ||
| Q2 25 | — | -894.2% | ||
| Q1 25 | — | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | — | -367.5% | ||
| Q2 24 | — | -676.6% | ||
| Q1 24 | — | -662.4% |
每股收益（稀释后）BEAMRXRX
| Q4 25 | $2.53 | $-0.17 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | — | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $1.2B | $1.1B |
| 总资产 | $1.5B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资BEAMRXRX
| Q4 25 | $1.2B | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务BEAMRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益BEAMRXRX
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $919.1M | ||
| Q1 25 | — | $933.9M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $524.6M | ||
| Q2 24 | — | $584.4M | ||
| Q1 24 | — | $401.2M |
总资产BEAMRXRX
| Q4 25 | $1.5B | $1.5B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $726.5M | ||
| Q2 24 | — | $775.9M | ||
| Q1 24 | — | $557.8M |
负债/权益比BEAMRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | $-47.3M |
| 自由现金流率自由现金流/营收 | -76.3% | -133.1% |
| 资本支出强度资本支出/营收 | 3.3% | 3.5% |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流BEAMRXRX
| Q4 25 | $-83.3M | $-46.1M | ||
| Q3 25 | — | $-117.4M | ||
| Q2 25 | — | $-76.4M | ||
| Q1 25 | — | $-132.0M | ||
| Q4 24 | — | $-115.4M | ||
| Q3 24 | — | $-59.2M | ||
| Q2 24 | — | $-82.2M | ||
| Q1 24 | — | $-102.3M |
自由现金流BEAMRXRX
| Q4 25 | $-87.0M | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率BEAMRXRX
| Q4 25 | -76.3% | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度BEAMRXRX
| Q4 25 | 3.3% | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率BEAMRXRX
| Q4 25 | -0.34× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
RXRX
暂无分部数据
